

Sebastien Calbo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9268512/publications.pdf>

Version: 2024-02-01

7
papers

682
citations

1684188

5
h-index

1872680

6
g-index

7
all docs

7
docs citations

7
times ranked

801
citing authors

#	ARTICLE	IF	CITATIONS
1	The Diversity of Serum Anti-DSG3 IgG Subclasses Has a Major Impact on Pemphigus Activity and Is Predictive of Relapses After Treatment With Rituximab. <i>Frontiers in Immunology</i> , 2022, 13, 849790.	4.8	1
2	FcRn Antagonism Leads to a Decrease of Desmoglein-Specific B Cells: Secondary Analysis of a Phase 2 Study of Efgartigimod in Pemphigus Vulgaris and Pemphigus Foliaceus. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	9
3	Rituximab and Corticosteroid Effect on Desmoglein-Specific B Cells and Desmoglein-Specific T Follicular Helper Cells in Pemphigus. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2132-2140.e1.	0.7	13
4	Longitudinal Pathogenic Properties and N-Glycosylation Profile of Antibodies from Patients with Pemphigus after Corticosteroid Treatment. <i>Biomedicines</i> , 2021, 9, 1411.	3.2	1
5	Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen. <i>Frontiers in Immunology</i> , 2019, 10, 1794.	4.8	20
6	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet</i> , The, 2017, 389, 2031-2040.	13.7	438
7	Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response. <i>Science Translational Medicine</i> , 2013, 5, 175ra30.	12.4	200